Novartis AG (NVS)
159.99
-3.10
(-1.90%)
USD |
NYSE |
Sep 04, 16:00
152.44
-7.55
(-4.72%)
Pre-Market: 20:00
Novartis Research and Development Expense (Quarterly) : 2.759B for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.759B |
| March 31, 2026 | 2.806B |
| December 31, 2025 | 2.837B |
| September 30, 2025 | 2.857B |
| June 30, 2025 | 2.658B |
| March 31, 2025 | 2.297B |
| December 31, 2024 | 2.529B |
| September 30, 2024 | 2.318B |
| June 30, 2024 | 2.276B |
| March 31, 2024 | 2.23B |
| December 31, 2023 | 2.142B |
| September 30, 2023 | 2.00B |
| June 30, 2023 | 2.302B |
| March 31, 2023 | 2.114B |
| December 31, 2022 | 1.112B |
| September 30, 2022 | 2.531B |
| June 30, 2022 | 2.268B |
| March 31, 2022 | 2.283B |
| December 31, 2021 | 2.402B |
| September 30, 2021 | 2.307B |
| June 30, 2021 | 2.313B |
| March 31, 2021 | 2.149B |
| December 31, 2020 | 2.338B |
| September 30, 2020 | 2.146B |
| June 30, 2020 | 2.441B |
| Date | Value |
|---|---|
| March 31, 2020 | 2.06B |
| December 31, 2019 | 2.853B |
| September 30, 2019 | 2.199B |
| June 30, 2019 | 2.051B |
| March 31, 2019 | 2.299B |
| December 31, 2018 | 2.232B |
| September 30, 2018 | 2.161B |
| June 30, 2018 | 2.120B |
| March 31, 2018 | 1.991B |
| December 31, 2017 | 2.502B |
| September 30, 2017 | 2.239B |
| June 30, 2017 | 2.062B |
| March 31, 2017 | 2.169B |
| December 31, 2016 | 2.584B |
| September 30, 2016 | 2.224B |
| June 30, 2016 | 2.19B |
| March 31, 2016 | 2.041B |
| December 31, 2015 | 2.472B |
| September 30, 2015 | 2.19B |
| June 30, 2015 | 2.206B |
| March 31, 2015 | 2.067B |
| December 31, 2014 | 2.537B |
| September 30, 2014 | 2.113B |
| June 30, 2014 | 2.220B |
| March 31, 2014 | 2.495B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Roche Holding AG | -- |
| AstraZeneca PLC | 3.456B |
| GSK Plc | 2.310B |
| Johnson & Johnson | 3.603B |
| Eli Lilly & Co. | 3.819B |